Abstract Purpose Actinium-225-labeled prostate-specific membrane antigen ([225Ac] Ac-
PSMA-617) is safe and effective in the treatment of metastatic castration-resistant prostate …

Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …

Background An updated systematic review and meta‐analysis of relevant studies to
evaluate the effectiveness of prostate‐specific membrane antigen (PSMA)‐targeted …

Summary Background Actinium-225 (225 Ac) prostate-specific membrane antigen (PSMA)
radioligand therapy (RLT) is a novel therapy for metastatic castration-resistant prostate …

Purpose Lutetium-177 prostate-specific membrane antigen-617 (177 Lu-PSMA-617) in end-
stage metastatic castration-resistant prostate cancer (mCRPC) has reported favourable …

Simple Summary Several strategies have demonstrated the ability to improve the survival of
patients with both metastatic and nonmetastatic prostate cancer. The old backbone of …

Abstract Background In prostate cancer (PCa), questions remain on indications for prostate-
specific membrane antigen (PSMA) positron emission tomography (PET) imaging and …

The aim of this retrospective analysis was to determine prostate-specific antigen (PSA)
response, PSA progression-free survival (PFS), and overall survival (OS) in a large cohort of …

Prostate-specific membrane antigen (PSMA), highly expressed in prostate cancer, is a
promising target for radionuclide therapy. Auger electron-emitting radionuclides are well …

There is now an increasing trend for targeting cancers to go beyond early diagnosis and
actually improve Progression-Free Survival and Overall Survival. Identifying patients who …